ERBB2 and breast cancer: Among the types of BC, KRT17 is a marker of triple-negative breast cancers (TNBCs) [18], and overexpression of KRT17 has been confirmed to be associated with poor prognosis in estrogen receptor (ER)−/HER2− BC patients [13].